

DETAILS

RELATIONS



International Journal of Cancer
Volume 146, Issue 2

Jan 2020

Pages 297-590

ARTICLE

Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer

[View article page](#)

Isabelle Ray-Coquard, David Cibula, Mansoor R. Mirza, Alexander Reuss, Caterina Ricci, N ... [See all authors](#)



¹¹AGO and Department of Gynecology, Klinikum der Stadt Ludwigshafen GmbH, Ludwigshafen, Germany

¹²NSGO and Department of Gynecology, Haukeland Universitetssykehus, Bergen, Norway

¹³Center for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway

¹⁴GINECO and Department of Gynecologic Cancer and Medical Oncology, Centre Oscar Lambret, Lille, France

¹⁵AGO and Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Germany

¹⁶NSGO and Department of Oncology, University Hospital Linköping, Linköping, Sweden

¹⁷AGO and Department of Gynecology and Obstetrics, Oberschwabenklinik, Krankenhaus St. Elisabeth, Ravensburg, Germany

*Collaborators are listed in the appendix

Additional Supporting Information may be found in the online version of this article.

Key words: antiangiogenic, nintedanib, ovarian cancer, overall survival, tyrosine kinase inhibitor

Abbreviations: AUC: area under the curve; CI: confidence interval; ENGOT: European Network of Gynaecological Oncological Trial; FIGO: International Federation of Gynecology and Obstetrics; GCIG: Gynecologic Cancer InterGroup; HR: hazard ratio; MRC: Medical Research Council; OS: overall survival; PARP: polyADP ribose polymerase; PFS: progression-free survival; TKI: tyrosine kinase inhibitor; VEGF: vascular endothelial growth factor

Conflict of interest: I.R.-C. received support for research and travel from Roche, Boehringer Ingelheim, AstraZeneca, Tesaro and PharmaMar. M.R.M. has received honoraria from AstraZeneca, Biocad, Clovis, Genmab, GSK, Karyopharm, Merck, Oncology Venture, Pfizer, Roche, Sera Prognostics, Sotio, Tesaro and Zai Lab, and study grants (to institution) from AstraZeneca, Boehringer Ingelheim, Clovis Oncology, Pfizer and Tesaro. N.C. received support for travel and participated in advisory boards with Roche, PharmaMar, AstraZeneca, Tesaro, Clovis, Pfizer, Biocad and Takeda. A.G.-M. received fees, honoraria or grants outside the subject of this article from Roche, AstraZeneca, Tesaro, GSK, Clovis, MSD, Pfizer, Novartis, PharmaMar and Imugene. L.B. receives project support from AstraZeneca and is a member of various ovarian cancer expert panels (Tesaro, Clovis Oncology and AstraZeneca). M.G.-M. has received honoraria for educational activities from AstraZeneca.

P.H. has received honoraria outside the submitted work from AstraZeneca, Roche, Sotio, Tesaro, Stryker, ASCO, Zai Lab and MSD. A.H. has received honoraria from AstraZeneca, Pfizer, PharmaMar, Roche Pharma AG and Tesaro. M.M. is an employee of Boehringer Ingelheim Pharma GmbH. A.d.B. received honoraria for advisory boards and educational activities outside the subject of this article from AstraZeneca, Roche, Tesaro, Clovis, Biocad, PharmaMar, Pfizer and Genmab. All remaining authors have declared no conflicts of interest.

Grant sponsor: Boehringer Ingelheim

DOI: 10.1002/ijc.32606

History: Received 26 Apr 2019; Accepted 24 Jun 2019; Online 5 Aug 2019

Correspondence to: Isabelle Ray-Coquard, MD, PhD, Centre Léon Bérard, Hesper Lab. EA 7425, Université Claude Bernard Lyon Est, 28 rue Laennec, 69008 Lyon, France, Tel.: +33-478782828, E-mail: isabelle.ray-coquard@lyon.unicancer.fr

Int. J. Cancer: **146**, 439–448 (2020) © 2019 UICC

Gérer les préférences

Accepter tout